Drug profile

The FDA adverse-event record for Tobramycin Ophthalmic

37 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Tobramycin Ophthalmic. Species, reactions, and outcomes follow.

#1309 of 2,679
by report volume (all drugs)
37
adverse-event reports
10.8%
death-coded share
Dog
most-reported species
Verify with FDA CVM →

Corpus placement

According to the FDA Center for Veterinary Medicine openFDA adverse-event extract, Tobramycin Ophthalmic ranks #1300 of 2679 by total reports (37). Death-coded-share rank requires at least 50 reports. National dual: Milbemycin Oxime + Spinosad is #1 of 2679 drugs by total adverse-event reports (149,624) at death-coded-share rank 965 of 1130 drugs with at least 50 reports (2.3%); separately, Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) is #1 highest death-coded share at 97.8% (report rank #821).

149,624
Milbemycin Oxime + Spinosad reports (#1)
97.8%
Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) death share (#1)
#1300
This drug, reports of 2679

Report volume reflects how common a breed or drug is and how often owners and vets file — not actual risk. Death-coded share ranks are limited to entries with enough reports to be meaningful. The two maps do not agree at #1.

Release-over-release change

What changed in the latest FDA data snapshot

PlainBreed reconstructed the prior snapshot from dated openFDA partitions through 2025 Q4, then compared it with the 2026-07-27 openFDA export. Tobramycin Ophthalmic has 37 reports now versus 37 in that prior snapshot: 0 the same number of (0.0%).

Report change
+0
Death-coded reports
+0
Death-coded share
+0.0 pts

This compares reported-event counts in two source snapshots. It does not establish a change in real-world risk, product safety, or disease incidence.

Subscribe to Tobramycin Ophthalmic changes

Signature read: death-coded share at 10.8% is the most distinctive stamp on Tobramycin Ophthalmic's FDA AER row.

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
37
Total Reports
4
Deaths Reported
10.8%
Death-coded share of reports

Active Ingredients

Tobramycin Ophthalmic

Administration Routes

UnknownOphthalmicIntraocularTopical

Species Affected

Dog 23
Cat 14

Most Affected Breeds

Domestic Shorthair 6
Domestic Mediumhair 4
Bichon Frise 3
Saint Bernard Dog 3
Dog (unknown) 2
Shih Tzu 2
Poodle - Miniature 2
Boxer (German Boxer) 2
Retriever - Labrador 2
Pug 1

Most Reported Reactions

Not eating 7
Tympanic rupture 6
Lethargy (see also Central nervous system depression in Neurological) 6
Anorexia 5
Other abnormal test result NOS 5
Hypersalivation 5
Dehydration 5
Not drinking 5
Ocular discharge 4
Ataxia 4
Corneal ulcer 4
Ear infection NOS 4

Outcome Breakdown

Ongoing
22 (59.5%)
Outcome Unknown
6 (16.2%)
Recovered/Normal
5 (13.5%)
Died
2 (5.4%)
Euthanized
2 (5.4%)

Tobramycin Ophthalmic Adverse Event Insights

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

What to do with this drug

A report does not prove a drug caused the reaction; consult a veterinarian before acting on this data.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

openFDA Animal & Veterinary Adverse Events (FDA CVM) for Tobramycin Ophthalmic (#1309 of 2,679 by report volume); death-coded 10.8%. PlainBreed drug row · death-coded share stamp 10.8% · vintage 2025.

Informational only. FDA adverse-event reports are voluntary and do not prove causation; consult a veterinarian before acting on them. Verify with FDA CVM →